Falcon Point Capital’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-4,602
| Closed | -$321K | – | 52 |
|
|
2020
Q2 | $321K | Sell |
4,602
-6,499
| -59% | -$453K | 1.57% | 27 |
|
|
2020
Q1 | $504K | Sell |
11,101
-1,907
| -15% | -$86.6K | 1.09% | 30 |
|
|
2019
Q4 | $846K | Sell |
13,008
-39,612
| -75% | -$2.58M | 1.08% | 30 |
|
|
2019
Q3 | $3.57M | Buy |
52,620
+2,715
| +5% | +$184K | 1.96% | 21 |
|
|
2019
Q2 | $3.55M | Buy |
49,905
+1,005
| +2% | +$71.6K | 1.91% | 22 |
|
|
2019
Q1 | $3.84M | Buy |
48,900
+10,667
| +28% | +$837K | 2.09% | 16 |
|
|
2018
Q4 | $3.24M | Sell |
38,233
-32,192
| -46% | -$2.73M | 1.94% | 19 |
|
|
2018
Q3 | $12.1M | Sell |
70,425
-20,540
| -23% | -$3.52M | 2.59% | 11 |
|
|
2018
Q2 | $11.8M | Sell |
90,965
-38,025
| -29% | -$4.91M | 2.31% | 12 |
|
|
2018
Q1 | $13.3M | Sell |
128,990
-25,586
| -17% | -$2.64M | 2.66% | 7 |
|
|
2017
Q4 | $13.2M | Sell |
154,576
-30,726
| -17% | -$2.62M | 2.23% | 15 |
|
|
2017
Q3 | $16.8M | Sell |
185,302
-9,160
| -5% | -$831K | 2.44% | 10 |
|
|
2017
Q2 | $14.7M | Sell |
194,462
-5,908
| -3% | -$447K | 1.99% | 18 |
|
|
2017
Q1 | $13.2M | Sell |
200,370
-62,916
| -24% | -$4.15M | 1.76% | 28 |
|
|
2016
Q4 | $16.7M | Buy |
263,286
+19,460
| +8% | +$1.23M | 2.24% | 18 |
|
|
2016
Q3 | $14.6M | Buy |
243,826
+149,299
| +158% | +$8.92M | 2.23% | 20 |
|
|
2016
Q2 | $7.03M | Sell |
94,527
-69,401
| -42% | -$5.16M | 1.21% | 41 |
|
|
2016
Q1 | $11M | Buy |
163,928
+67,261
| +70% | +$4.49M | 1.89% | 23 |
|
|
2015
Q4 | $6.54M | Buy |
96,667
+46,988
| +95% | +$3.18M | 1.41% | 38 |
|
|
2015
Q3 | $2.65M | Buy |
+49,679
| New | +$2.65M | 0.95% | 41 |
|